Actimed Therapeutics and Mankind Pharma Sign Strategic Licensing Agreement for Cachexia Therapy in South Asia
Mumbai: Actimed Therapeutics Ltd, a UK-based clinical-stage specialty pharmaceutical company, has announced a strategic licensing agreement with Mankind Pharma Limited, one of India’s leading pharmaceutical companies and a shareholder in Actimed. The agreement grants Mankind exclusive rights to develop and commercialise Actimed’s novel cachexia therapies—including S-pindolol benzoate (ACM-001.1)—across India and South Asian territories.
The licensing deal covers India, Bangladesh, Bhutan, Nepal, Sri Lanka, and Myanmar, and includes Actimed’s patents, proprietary know-how, and future related intellectual property. Mankind will lead development, manufacturing, and commercialisation efforts under its own trademarks, specifically for the treatment and prevention of cachexia—a debilitating condition commonly associated with cancer and other chronic illnesses.
“Cachexia remains an area of significant unmet medical need, with no globally approved therapies to date,” said Robin Bhattacherjee, CEO, Actimed Therapeutics. “This agreement with Mankind marks a major step forward in our mission to deliver meaningful treatment options to patients worldwide.”
The licensed product, S-pindolol benzoate (ACM-001.1), is currently advancing toward Phase 2b/3 clinical development for cancer cachexia. Subject to successful trials and regulatory approvals, Mankind will commercialise the therapy across the designated territories.
“Mankind has been a long-term supporter of Actimed, and we are proud to deepen our partnership through this strategic agreement,” said Atish Majumdar, Senior President (Sales & Marketing), Mankind Pharma, and Non-Executive Director, Actimed. “Together, we aim to improve the lives of patients affected by cachexia across the Indian subcontinent.”
The collaboration reflects a shared commitment to innovation and patient-centric care, combining Actimed’s research expertise with Mankind’s robust development and commercial capabilities in South Asia.
